Apolipoprotein E genotype regulates amyloid-beta cytotoxicity. by Wilhelmus, M.M.M. et al.






The following full text is a publisher's version.
 
 





Please be advised that this information was generated on 2018-07-07 and may be subject to
change.
Neurobiology of Disease
Apolipoprotein E Genotype Regulates Amyloid-
Cytotoxicity
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Marcel M. Verbeek1,2
Departments of 1Neurology and 2Pathology, Radboud University Nijmegen Medical Center, 6500 HB Nijmegen, The Netherlands, and 3Department of
Medicine, Health Sciences Center, Stony Brook University, Stony Brook, New York 11794-8153
The 4 allele of apolipoprotein E (ApoE) is a risk factor for Alzheimer’s disease (AD), whereas the 2 allele may be relatively protective.
Both alleles are risk factors for cerebral amyloid angiopathy (CAA)-related hemorrhages. CAA is associatedwith degeneration of smooth
muscle cells and pericytes. Previously, we described that synthetic amyloid-1–40 peptide (A1–40) with the
22Glu3Gln “Dutch” muta-
tion caused pericyte death in vitro by amechanism that involves A fibril-like assembly at the cell surface. It is known that ApoE binds to
A andmaymodify its biological activities. In the present study, we evaluated the effect of ApoE onA-mediated toxicity of cerebrovas-
cular cells. We observed that cultured cells with an 4/4 genotype were more vulnerable to A than cultures with an 3/3 or 3/4
genotype. The one cell culture with the 2/3 genotype was relatively resistant to A compared with other cultures. Furthermore, we
observed a dose-dependent protective effect of native ApoE against A-mediated toxicity of cerebrovascular cells and, in addition, ApoE
2/3 cells secreted more ApoE protein compared with cells with other ApoE genotypes, in particular, compared with 4/4 cells. Thus,
the disparity between ApoE genotype and A-mediated toxicity might be related to differences in the cellular capacity to secrete ApoE.
The present data suggest that one mechanism by which ApoE may alter the risk for AD is a genotype-dependent regulation of A
cytotoxicity, possibly via variations in its secretion levels, whereby extracellular ApoEmay bind to A and therebymodify A-mediated
cell death.
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Introduction
Senile plaques (SPs) and cerebral amyloid angiopathy (CAA) are
two of the neuropathological hallmarks of Alzheimer’s disease
(AD). The amyloid- protein (A), which consists of 40–42
amino acids, is the major constituent of both SPs and CAA. Apo-
lipoprotein E (ApoE) has been identified as amajor risk factor for
the sporadic late-onset form of AD. The ApoE gene has three
alleles (2, 3, and 4), the most frequent of which is the 3 allele.
Inheritance of one or two copies of the 4 allele is associated with
a dose-dependent increased risk for AD and an earlier age of
onset of AD (Corder et al., 1993; Saunders et al., 1993), although
individuals homozygous for 4 may reach a high age without
cognitive impairment (Henderson et al., 1995). On the contrary,
the 2 allele seems to have a protective effect against AD (Corder
et al., 1994). Surprisingly, however, both the 2 and the 4 alleles
are associated with an increased risk for CAA or CAA-related
hemorrhages (Greenberg et al., 1996, 1998; Premkumar et al.,
1996; Nicoll et al., 1997).
Inheritance of one or two copies of the ApoE 4 allele is asso-
ciated with a higher load of SPs and CAA (Schmechel et al., 1993;
Premkumar et al., 1996). In vitro studies have shown that ApoE is
able to bind to A (Strittmatter et al., 1993; Pillot et al., 1999);
native ApoE3 binds Amore efficiently than ApoE4 (LaDu et al.,
1994). ApoE may also accelerate the formation of A fibrils
(Strittmatter et al., 1993; Sanan et al., 1994; Wisniewski et al.,
1994). In mice transgenic for human amyloid precursor protein
(APP) and deficient inApoE, the amount of amyloid, but not that
of A immunoreactivity, was strongly reduced compared with
transgenic APP/ApoE/ mice (Bales et al., 1999), suggesting
that ApoE plays a critical role in facilitating A deposition. In
contrast to these studies, early A deposition is suppressed in
mice transgenic for both APP and human ApoE on an ApoE
knock-out background (Holtzman et al., 1999). These results
show that the role of ApoE and its specific isoforms in A fibril-
logenesis, deposition, or clearance still remains unclear.
Previously, we described the toxicity of various A peptides
toward cultures of human brain cerebrovascular smooth muscle
cells (SMCs) andhumanbrain pericytes (HBPs) (Davis-Salinas et
al., 1995; Davis and Van Nostrand, 1996; Verbeek et al., 1997).
We demonstrated that nonaggregated wild-type A1–42 and
A1–40 carrying the Glu3Gln mutation at position 22 of A, as
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in hereditary cerebral hemorrhage with amyloidosis-Dutch type,
caused degeneration of cultured SMCs andHBPs. Either cell type
secreted significant amounts of ApoE (Verbeek et al., 1999).
Given the well described interactions between ApoE and A, we
investigated whether endogenously produced ApoE could inter-
fere in an isoform-dependent manner with the A-mediated cy-
totoxicity toward cultured human cerebrovascular cells. There-
fore, in this study, we performed a comparative analysis of the
cytotoxic effect of A on cultures of HBPs and SMCs with differ-
ent ApoE genotypes.
Materials andMethods
Reagents. A with the “Dutch” mutation (22 Glu3Gln; D-A1–40; 89%
pure) was purchased from Biosource (Etten-Leur, The Netherlands).
Human recombinant ApoE produced in baculovirus in Sf insect cells was
obtained from PanVera (Madison, WI). ApoE obtained from the condi-
tioned medium of transfected human embryonic kidney 293 (HEK293)
cells was generously provided byDr. G.W. Rebeck (GeorgetownUniver-
sity, Washington, DC). Affinity-purified polyclonal anti-A antibodies
were prepared as described previously (Davis-Salinas et al., 1994).
Monoclonal anti-ApoE antibody was purchased from Innogenetics
(Antwerpen, Belgium). Anti-low-density lipoprotein receptor-related
protein (LRP) (-chain) antibody was obtained from American Diag-
nostica (Stamford, CT). Anti-A antibody used for CAA grading was
purchased from Dako (Glostrup, Denmark).
Cells. Pericytes were isolated fromhuman brain tissue, and SMCswere
isolated from leptomeningeal vessels from a number of AD patients and
neurologically unaffected individuals, obtained after autopsy as de-
scribed previously (Verbeek et al., 1994, 1995, 2002) (Table 1). Diagnosis
and grading of AD patients was performed according to the criteria es-
tablished by Braak and Braak (1991), Mirra et al. (1991), and The Na-
tional Institute on Aging and Reagan Institute Working Group on Diag-
nostic Criteria for the Neuropathological Assessment of Alzheimer’s
Disease (1997). CAA grading was established by quantification of the
number of A-positive vessels in one microscopic field (magnification,
2.5). At least fourmicroscopic fields of both the occipital cortex and the
gyrus temporalis medius were analyzed and categorized as follows: 0 (,
no CAA), 0–10 (, sparse CAA), 10–20 (, moderate CAA), and20
(, severe CAA).
Both HBPs and SMCs were maintained in Eagle’s modification of
essentialmedium (EMEM) supplementedwith 10%human serum (San-
quin Blood Bank,Nijmegen, TheNetherlands), 20%newborn calf serum
(Invitrogen, Paisley, UK), recombinant basic fibroblast growth factor (1
ng/ml), heparin (5 U/ml; Organon, Boxtel, The Netherlands), and anti-
biotics. Immunoelectronmicroscopical detection of A accumulating at
the surface of cultured cells was performed as described previously (Ren-
sink et al., 2002, 2004). With respect to the various types of experiments,
we did not observe differences between cerebrovascular cell cultures with
the sameApoE genotype but derived fromdifferent types of patients (i.e.,
AD or control patients).
Degeneration experiments.Triplicate wells with cultured cells were pre-
incubated with serum-free medium (EMEM with 0.1% BSA and antibi-
otics) for 4 h. Subsequently, cells were incubated with fresh serum-free
medium supplemented with synthetic A peptides at 25M for 6 d. Cells
were routinely inspected and photographed using an Olympus (Tokyo,
Japan) phase-contrast microscope. Cell viability was quantitated using a
fluorescence live/dead cell assay according to the description of theman-
ufacturer (Molecular Probes, Leiden, The Netherlands). The cultures
were examined using an Olympus fluorescencemicroscope, and the per-
centage of dead cells was determined from counting in at least five mi-
croscopic fields per well. Based on previous studies (Davis and Van Nos-
trand, 1996; Verbeek et al., 1997), D-A1–40 was used, because this
peptide induced a robust degeneration of both pericytes and SMCs.
Western blot analysis. Cells were grown in serum-free medium, and
both culture supernatant and cell lysates were collected to examine se-
creted and cell-associated expression of proteins, respectively. Culture
supernatant was diluted 1:1 with reducing sample buffer. Cells were
washed twice with PBS and then solubilized in the wells with lysis buffer
[50 mM Tris-HCl, 150 mM NaCl, pH 7.5, 1% SDS, 5 mM EDTA, 500 M
4-(2-aminoethyl)benzenesulfonyl fluoride, 10 g/ml leupeptine, and 10
g/ml chymostatin] for 15 min. The protein content of diluted samples
of the cell lysates was determined using the bichinchonic acid method
(Pierce, Rockford, IL). Equal protein amounts were loaded, fractionated
on SDS-polyacrylamide gels, and subsequently electrophoretically trans-
ferred to nitrocellulose membranes (Schleicher and Schuell, Hertogen-
bosch, TheNetherlands) in blotting buffer (25mMTris-HCl, pH 8.6, 192
mM glycine, and 20% methanol). Blots were washed for 15 min in PBS
containing 0.05% Tween 20 (PBST), preincubated with blocking solu-
tion (5% lowfat milk powder in PBST), washed three times with PBST,
and subsequently incubated with primary antibodies and peroxidase-
labeled secondary rabbit anti-mouse antibodies (Dako). Detection was
performed by chemiluminescence according to the description of the
manufacturer (Boehringer Mannheim, Almere, The Netherlands) and
exposure to Kodak (Rochester, NY) X-OMAT-R films.
ApoE genotyping. DNA was isolated from small pieces of brain tissue,
from which cell cultures were also derived, using a DNA isolation kit
(Biozym, Landgraaf, The Netherlands). ApoE genotype was determined
using PCR andHhaI restriction analysis according tomethods described
previously (Hixson and Vernier, 1990; Wenham et al., 1991).
ApoE quantification. ApoE secretion by cultured HBPs and SMCs was
quantitated both by scanning ofWestern blots and by ELISA. The chemi-
luminescent signal of both ApoE standards (PanVera,Madison,WI), cell
lysates, and culture supernatants obtained after Western blotting was
scanned with a LabScan (Amersham Biosciences, Aylesbury, UK). For
ELISA, 5 g/ml affinity-purified goat anti-ApoE (Biodesign Interna-
tional, Saco, ME) was coated overnight at 4°C on a 96-well plate. Subse-
quently, wells were incubated with 1% nonfat milk in PBST to block
Table 1. Overview of the source of HBP and SMC cell cultures
Number Diagnosis Grade (Braak) Grade (CERAD) CAA grade Cell type PMI (h) ApoE Age Gender Cause of death Vascular risk factors
1 Control II   HBP/SMC 5 2/3 84 F Cardiac failure Atherosclerosis
2 AD VI   HBP 4 3/3 94 F Respiratory insufficiency Atherosclerosis
3 AD VI   HBP 4 3/3 81 F Cardiac failure None
4 AD VI   HBP/SMC 3 3/3 75 M Pneumonia Atherosclerosis
5 Control 0 0  HBP/SMC 4 3/3 84 F Pneumonia Atherosclerosis
6 Control 0 0  SMC 6 3/3 71 F Ruptured aortic aneurysm Atherosclerosis
7 AD V   SMC 6 3/3 87 F Bronchopneumonia Atherosclerosis
8 AD/PD V   SMC 4 3/4 91 F Pneumonia Atherosclerosis
9 AD V   HBP 5 3/4 84 M Cardiac failure Atherosclerosis
10 Control III   HBP/SMC 4 3/4 83 F Ruptured aortic aneurysm Atherosclerosis
11 AD VI   HBP/SMC 3 3/4 89 F Pneumonia Atherosclerosis
12 AD VI   HBP 5 4/4 83 F Sepsis Atherosclerosis
13 AD VI   HBP/SMC 3 4/4 69 M Unknown Atherosclerosis
F, Female; M, male; PD, Parkinson’s disease; PMI, postmortem interval in hours. Grading of AD (Braak and CERAD scores) and CAA was performed as described in Materials and Methods.
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specific binding, with ApoE standards (PanVera, or from transfected
HEK293 cells) or (diluted) culture supernatants, with affinity-purified
biotinylated goat anti-ApoE (Biodesign International), and finally with
peroxidase-labeled avidin (Dako). Tetramethylbenzidinwas used as sub-
strate, and H2SO4 was used to terminate the peroxidase reaction. No
significant differences were observed with either type of standards; the
use of ApoE3 as a standard only resulted in slightly higher signals than
with ApoE4.
Partial purification of ApoE from culture supernatant. Purification of
extracellular ApoE protein from medium of cultured HBP was per-
formed as described byDeMattos et al. (1999) withminormodifications.
Cells were incubated with serum-free EMEM medium for 6 d. Cells
remained viable during this period. Supernatantwas collected andpassed
through a D100 weakly basic anion exchange filter (Sartorius, Goettin-
gen, Germany) and eluted with 1 M ammonium bicarbonate. The eluted
ApoE was recirculated over a HiTrap heparin column (Amersham Bio-
sciences). Fractions containing ApoE were pooled and dialyzed against
PBS. Using the ApoE sandwich ELISA described above and comparing
the ApoE concentration with the total protein amount, it was demon-
strated that, in the purified fractions, 25% of the total protein amount
consisted of ApoE.
RNA isolation and Northern blot analysis. Total RNA (8 g) was iso-
lated from cultured cells by using the RNeasy kit (Qiagen, Hilden, Ger-
many) according to the protocol of the manufacturer. Total RNA was
treated with formaldehyde (Sambrook et al., 1989), separated on a 1.5%
agarose gel, and blotted onto a Hybond N membrane (Amersham
Biosciences). A 1100 bp fragment containing human ApoE3 cDNA (a
kind gift from Dr. G. W. Rebeck, Georgetown University) was released
from a pCMV4 expression vector by XbaI and KpnI restriction cleavage.
ApoE cDNA probe was radiolabeled by 32dCTP incorporation using a
random-primed DNA labeling kit (Roche Diagnostics, Penzberg, Ger-
many). After preincubation in a hybridizationmix (0.25 M sodium phos-
phate buffer, pH 7.2, 7% SDS, 1% BSA, 1 mM EDTA, and 0.1 mg/ml
single-strand salmon sperm DNA) at 65°C, membranes were hybridized
overnight with the radiolabeled probes under the same conditions. Blots
were then washed at 58°C with 0.25 M sodium phosphate buffer, pH 7.2,
1% SDS, and 1 mM EDTA and autoradiographed using Kodak
X-OMAT-S films.
Results
HBPs and SMCs were isolated from 10 and 9 donor brains, re-
spectively. The characterization of HBPs and SMCs has been de-
scribed extensively in previous studies (Verbeek et al., 1994,
2002). The cultured cells were divided into four different groups
according to their ApoE genotype: 2/3, 3/3, 3/4, and 4/4
(Table 1).
After 4 –6 d of treatment with 25 M, D-A1–40 cultured
cells (HBPs or SMCs) lost their characteristic polygonal shape,
individual cell contours became less evident, and signs of cel-
lular atrophy were observed (data not shown). Because ApoE is
codeposited with amyloid in the vessel walls in CAA, we deter-
mined whether ApoE production by perivascular cells was af-
fected by D-A1–40 treatment as well. In the absence of A treat-
ment, both cultured SMCs and HBPs secreted considerable
amounts of ApoE into the culture medium, as shown byWestern
blot analysis (Fig. 1). In contrast, smaller amounts of ApoE were
associated with the cells. In contrast, incubation with D-A1–40
resulted in an inversion of ApoE distribution, with most of the
ApoE remaining associated with the cells. This was confirmed by
double-immunofluorescence staining of D-A1–40-treated cells,
showing that both A and ApoE were coassociated on the cell
surface (data not shown).
These experiments suggested that an interaction occurred be-
tween the endogenously produced ApoE and the exogenously
administered A that accumulated on the cell surface (Fig. 2).
Therefore, we investigated whether the ApoE genotype of the
cultured cells affected the toxicity of D-A1–40. The results
showed that there were striking differences in the response to
D-A1–40 between cell cultures with a different ApoE genotype.
After treatment of HBP cultures with the 4/4 genotype with
D-A1–40 for 6 d, the number of viable cells was strongly reduced
(Fig. 3). In contrast, cells with either the 3/3 or the 3/4 geno-
type were consistently less susceptible to D-A1–40 treatment. In
addition, although only a single 2/3 HBP culture was available,
we consistently observed (n 9 experiments) that cell death was
much lower (mean, 12  10% dead cells). In addition, similar
results were obtained with SMC cultures of various ApoE geno-
types (data not shown). Both HBPs and SMCs expressed the
ApoE receptor LRP. The effects described above, however,
could not be explained by differences in LRP expression of the
cells, which was similar in the cell cultures with different ApoE
genotypes (data not shown). Furthermore, the effects also
could not be explained by differences in the clinicopathologi-
cal state of the donors [Braak or The Consortium to Establish
a Registry for Alzheimer’s Disease (CERAD) grade of AD, CAA
grade] (Table 1).
Figure 1. Western blot analysis of cell-associated (Cells) and secreted (Medium) ApoE in
cultured human brain pericytes treated for 6 d with 25 M D-A1–40. In untreated cultures
(Control),most ApoE (molecularweight,37 kDa)was present in the supernatant, whereas in
D-A1–40-treated cells (D-A1–40), ApoE was predominantly associated with the cellular
fraction.
Figure 2. Immunoelectron microscopy analysis of HBP for localization of A after 3 d of
incubation with D-A1–40 (25M), showing decoration of A fibrils extending from the cell
surface. Magnification, 6000.
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These data suggested that ApoE protein modulated the asso-
ciation of Awith the cell surface and subsequent cellular degen-
eration.We therefore investigatedwhether simultaneous incuba-
tion of cells with D-A1–40 and ApoE would lead to an ApoE
isoform-dependent effect on HBP death. Addition of either
ApoE3 or ApoE4 (up to 1.6 g/ml), obtained from supernatants
of transfected HEK293 cells, resulted in a slight but nonsignifi-
cant decrease in D-A1–40-induced cell death (Fig. 4, left). The
addition of any of the three ApoE isoforms (between 1.5 and 12
g) produced by baculovirus in Sf insect cells yielded a small but
significant decrease in cell death of cultured HBPs (Fig. 4, mid-
dle). Remarkably, when HBP cultures were coincubated with D-
A1–40 and conditioned supernatant of either 2/3 or 4/4HBP
cultures, a dramatic decrease in cell death was observed (Fig. 4,
right). This effect was stronger when culture supernatant was
used from 2/3 cells compared with that from 4/4 cells. Addi-
tion of ApoE, semipurified from conditionedHBP culture super-
natants (up to 20 l; containing 0.25 g of ApoE), resulted in a
dose-dependent decrease in cellular toxicity (Fig. 5).
We then studied whether the differential response of HBPs
with different ApoE genotypes could be explained by differences
in the ApoE production capacity of the cells. ApoE production by
cells with the 4/4, 3/4, or 3/3 genotypewas not significantly
different ( p  0.55; ANOVA), although we observed a trend
toward lowest production by HBP 4/4 cultures (Fig. 6). In two
of three experiments, HBP 4/4 cultures produced the smallest
amounts of ApoE of all cultures. Interestingly, although based on
only one HBP culture, cells with the ApoE 2/3 genotype pro-
duced a mean 5.0 3.1 ng of ApoE per gram of protein per day
(n 3 experiments), which is a factor threefold to 12-fold higher
than the other cell cultures ( p 0.02 vs ApoE 3/3; p 0.21 vs
ApoE 3/4; p  0.01 vs ApoE 4/4). Similar results were ob-
tainedwith SMCcultures of varying genotype, with the exception
of one SMC 3/3 culture that consistently secreted high ApoE
levels comparable with that of the 2/3 cell cultures. In the SMC
cultures, cells with the ApoE 2/3 genotype produced a mean
13.9 5.4 ng of ApoE per microgram of protein per day (n 3
experiments), which is a factor 4–12 higher than the other cell
cultures ( p 0.01 vs ApoE 3/3; p 0.0001 vs ApoE 3/4; p
0.02 vs ApoE 4/4; data not shown). Effects onApoE production
by the cultured cells were not correlated to differences in the
clinicopathological state of the donors (Braak orCERADgrade of
AD, CAA grade) (Table 1).
Finally, ApoE mRNA levels in both HBP and SMC cultures
were analyzed using Northern blot analysis. Although we did not
observe a perfect match between protein secretion and mRNA
levels, this analysis showed that the cells with the 2/3 genotype
contained the highest levels of ApoE mRNA, whereas the cells
with the 4/4 genotype contained the lowest levels (Fig. 7).
There was some heterogeneity in the mRNA levels in the 3/3
and 3/4 cells. The same SMC culture with the 3/3 genotype
that secreted large amounts ofApoEprotein also contained a high
level of ApoE mRNA, comparable with that in the 2/3 cell
culture.
Figure 4. Effect of the presence of ApoE obtained from transfected HEK293 cells (left; 1.65g of ApoE3/4) or produced by baculovirus in Sf insect cells (middle; 1.5g of ApoE2/ApoE3/ApoE4)
on thenumber of dead cells in cultures of humanbrain pericytes treatedwith 25MD-A1–40. Addition ofHEK293ApoE3/4didnot affect thenumber of dead cells inducedby exposure toD-A1–40
(left). Addition of any of the ApoE isoforms produced by Sf insect cells moderately, but significantly, decreased D-A1–40-induced cell death (middle). Right, Incubation with conditionedmedium
obtained from either 2/3 (E2/E3) or 4/4 (E4/E4) cells (indicated in the inset) significantly decreased the number of dead cells in HBP cultures with an 2/3 or 4/4 genotype (indicated on
the x-axis). Level of significance, *p 0.05; **p 0.01; ***p 0.001. n.s., Not significant.
Figure 3. Comparison of the effect of treatment with 25 M D-A1–40 for 6 d of human
brain pericyte cultures with different ApoE genotypes. Cultured HBPs with the ApoE 4/4
genotype demonstrated more cell death than HBP cultures with the ApoE 3/4 or 3/3
genotype. Significance of the observed differences is as follows (ANOVA with Tukey’s post hoc
test for multiple comparisons): 4/4 versus 3/4 or 3/3, p 0.001; 3/3 versus 3/4,
p 0.05.
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Discussion
Because of the initial reports of the association of the ApoE 4
genotype with the development of AD, many research groups
have tried to identify a biological explanation for this epidemio-
logical observation. ApoE binds to A and affects its fibrillogen-
esis, possibly in an isoform-specific manner (LaDu et al., 1994;
Ma et al., 1994; Wisniewski et al., 1994). In other studies,
isoform-specific neurotrophic or neurotoxic effects for ApoE
have been described previously (Holtzman et al., 1995; DeMattos
et al., 1998; Sun et al., 1998). In the present study, we provide a
novel explanation thatmay, in part, account for the association of
ApoE with AD development. The major findings of this investi-
gation are as follows. First, the degree of A-mediated toxicity of
human cerebrovascular cells is dependent on the ApoE genotype
of the cells. Cultured HBPs with an ApoE 4/4 genotype were
more vulnerable to A-mediated cytotoxicity than cells with
other ApoE genotypes. Second, ApoE protein causes a direct,
concentration-dependent inhibition of A-mediated toxicity of
human cerebrovascular cells. Third, the production level of ApoE
protein may, at least in part, depend on the ApoE genotype.
It has been suggested that in the brain, a balance exists be-
tween A deposition and A removal. A removal from the
brainmay occur by several mechanisms. For example, ApoEmay
play a role in internalization and subsequent degradation of A
and in A clearance via transport to the circulation. A may be
internalized and degraded by smooth muscle cells (Urmoneit et
al., 1997) and by astrocytes (Koistinaho et al., 2004), a process
that is facilitated by ApoE, because astrocytes derived from
ApoE/ mice do not degrade A deposits in the brain. Alter-
natively, A may be cleared from the brain via transport across
the blood–brain barrier (BBB). LRP-1 binds free A and possibly
is the major receptor mediating A internalization (Urmoneit et
al., 1997; Koistinaho et al., 2004) and its efflux from the brain to
the circulation (Shibata et al., 2000). LRP-1 most efficiently re-
moves wild-type A1–40, whereas A peptides containing a
higher percentage of -sheet structures (such as wild-type A42
and D-A1–40) bind less efficiently, leading to accumulation of
A in brainmicrovessels (Deane et al., 2004). ApoE, which is also
a ligand for LRP-1,may facilitate the clearance ofA from the brain,
because clearancewas significantly reduced inApoE/mice (Shi-
bata et al., 2000). Therefore, it is possible that at least part of the
cerebral A forms complexes with ApoE and that such complexes
via ApoE–LRP-1 interactions may be either degraded by astrocytes
or cleared from the brain by transport over the BBB. However, al-
though the existence of such complexes in the brain has been dem-
onstrated previously (Russo et al., 1998), their possible interaction
with LRP-1 has not yet been studied.
Thus, high cerebral concentrations of
ApoE may inhibit deposition of A in the
form of SPs and CAA. Our in vitro data
suggest that, at least at the vascular level,
ApoE abrogates the pathological interac-
tion of A with vascular cells and retains
A in a conformation that does not result
in its assembly at the cell surface, possibly
by a diminished interaction with LRP-1.
These findings are in line with the obser-
vation that human ApoE, in an isoform-
specific way, suppresses A deposition in
both young and aged APP-V717F trans-
genic mice (Holtzman et al., 1999; Fagan
et al., 2002). Furthermore, human ApoE
delays the shift inA from soluble pools to
Figure 5. Addition of ApoE, semipurified from supernatants of cultured HBPs, reduced D-
A1–40 (12.5M)-mediated HBP cell death in a concentration-dependent way.
Figure 6. Quantification of ApoE secretion by cultured HBPs with the ApoE 3/3, 3/4,
and 4/4 genotypes by ELISA. ApoE production by cells with the 4/4, 3/4, or 3/3
genotype was not significantly different ( p 0.55; ANOVA), although we observed a trend
toward lowest production by HBP 4/4 cultures.
Figure 7. Northern blot analysis of ApoE mRNA expression (top) in cultured HBPs (A) and SMCs (B). Bottom, The levels of 28S
and 18S RNA are shown as a control for RNA loading. ApoEmRNAexpressionwas variable, but cellswith the ApoE4/4 genotype
consistently contained the smallest amounts of ApoEmRNA,whereas the (single) cultureswith the2/3 genotype produced the
highest amounts of ApoE mRNA.
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insoluble pools in these animals, which is in agreement with our
observations of decreased accumulation of A at the cell surface in
the presence of elevated ApoE concentrations (Fagan et al., 2002).
Thus, relatively high concentrations of cerebral ApoE are ben-
eficial. It can be anticipated that the levels of free cerebral ApoE
are reflected by its concentration in CSF. It has been reported,
however, that the CSF concentration of ApoE is similar in both
control and AD groups with different ApoE genotypes (Lehti-
maki et al., 1995; Yamauchi et al., 1999), although a trend toward
elevated ApoE levels in patients carrying the 2 allele was ob-
served (Lehtimaki et al., 1995). However, because the applied
assays have all been designed to detect unboundApoE, it remains
possible that the levels of CSF A–ApoE complexes will be differ-
ent among individuals with different ApoE genotypes.
It has been suggested by Nicoll et al. (1997) and Greenberg et
al. (1998) that both the 2 and 4 alleles are risk factors for CAA-
related hemorrhages, the latter by increasing the vascular amy-
loid load and the former by increasing the susceptibility of the
vessel for rupture. By incorporating these suggestions in our in
vitromodel, one would predict increased cell death in cells carry-
ing the 2 allele, because this would lead to vessel weakening by
(A-mediated) degeneration of SMCs or HBPs. However, our in
vitro data show less cytotoxicity associated with cells possessing
an 2 allele. Perhaps the 2 allele promotes other changes leading
to vessel rupture, such as increased extracellular proteolysis.
ApoE produced by cerebrovascular cells may play a promi-
nent role in the pathogenesis of CAA. Second only to the liver, the
brain is the organ that produces the largest amount of ApoE.
Astrocytes are regarded as the major source of cerebral ApoE
(Boyles et al., 1985), although neurons may be able to produce
ApoE as well (Xu et al., 1999). Here, we demonstrated that both
pericytes and SMCs secrete ApoE and, because both are located at
the abluminal side of the blood–brain barrier, they may contrib-
ute to the pool of cerebral ApoE. This may be particularly impor-
tant with regard to the etiology of CAA. An attractive model
explaining the pathogenesis of vascular A deposition has been
proposed by Weller et al. (1998), who suggested that A of neu-
ronal origin might be transported from the brain parenchyma to
the vasculature by drainage of interstitial fluid. Experimental
support for this model was provided by the transgenicmice stud-
ies by Calhoun et al. (1999), who demonstrated extensive CAA
formation in APP transgenic mice under the control of the neu-
ronal Thy-1 promotor. This model of CAA formation requires
the availability of local factors that enhance or otherwise stimu-
late A deposition in the vasculature. The availability of vessel-
derived ApoE, but possibly also factors such as heparan sulfate
proteoglycans (van Horssen et al., 2001), may regulate A clear-
ance and/or deposition in the vasculature. Our data suggest that
when ApoE is available in high-enough concentrations, Amay
remain solubilized and be processed for clearance, whereas if
ApoE is available in restricted amounts only, A will be prone to
deposition and cell-surface aggregation in the vessel wall.
The degree of lipidation of the ApoE molecule is crucial to its
biological activities. Circulating ApoE is tightly bound to several
classes of lipoproteins, such as high-density lipoprotein and very-
low-density lipoprotein. It was demonstrated previously that
lipidated and unlipidated ApoE differentially interact with A,
suggesting that the degree and type of lipidation of ApoE are of
critical importance (LaDu et al., 1994). In accordance with this
study, we observed differences in the reduction of A-induced
cellular toxicity ofHBPs byApoE, dependent on its source; ApoE,
especially when secreted byHBPs, seemed very efficient. Previous
studies by DeMattos et al. (1998) and Sun et al. (1998) showed
that ApoE is secreted by cultured cells as specific lipid-containing
particles different from those inCSF (LaDu et al., 1998). Our data
suggest that between different cell types (HEK293 cells vs HBPs/
SMCs), the degree ofApoE lipidationmay vary. The recombinant
ApoE from PanVera is posttranslationally modified, but lipida-
tion of the molecule is probably also different in Sf insect cells
compared with HBPs.
Our comparative analysis of ApoE protein secretion and
mRNA levels by the respective HBP and SMC cell cultures sug-
gests that not only the ApoE genotype but also other unstudied
factors may affect ApoE secretion (e.g., ApoE promotor poly-
morphisms) (Artiga et al., 1998) or factors involved in lipid me-
tabolism. Furthermore, although we did not collect any evidence
in this direction, we cannot completely exclude the possibility that
the original cerebral environment of the cells (i.e., AD, control, or
other diagnosis) contributes to the cellular phenotype in vitro. Fi-
nally, future studies on other cerebral cell types will have to reveal to
what extent ApoE will affect other cellular responses to A, includ-
ing neuronal cell death and glial cytokine production.
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